Notice: This company has been marked as potentially delisted and may not be actively trading. RXi Pharmaceuticals (RXII) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends RXII vs. VTVT, CASI, XCUR, KZR, ALRN, RFL, BIVI, NBRV, VIRI, and GANXShould you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include vTv Therapeutics (VTVT), CASI Pharmaceuticals (CASI), Exicure (XCUR), Kezar Life Sciences (KZR), Aileron Therapeutics (ALRN), Rafael (RFL), BioVie (BIVI), Nabriva Therapeutics (NBRV), Virios Therapeutics (VIRI), and Gain Therapeutics (GANX). These companies are all part of the "medical" sector. RXi Pharmaceuticals vs. vTv Therapeutics CASI Pharmaceuticals Exicure Kezar Life Sciences Aileron Therapeutics Rafael BioVie Nabriva Therapeutics Virios Therapeutics Gain Therapeutics RXi Pharmaceuticals (NASDAQ:RXII) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends. Which has more risk & volatility, RXII or VTVT? RXi Pharmaceuticals has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Does the media prefer RXII or VTVT? In the previous week, vTv Therapeutics had 1 more articles in the media than RXi Pharmaceuticals. MarketBeat recorded 1 mentions for vTv Therapeutics and 0 mentions for RXi Pharmaceuticals. vTv Therapeutics' average media sentiment score of 0.49 beat RXi Pharmaceuticals' score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment RXi Pharmaceuticals Neutral vTv Therapeutics Neutral Do insiders & institutionals believe in RXII or VTVT? 9.6% of RXi Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 1.0% of RXi Pharmaceuticals shares are owned by insiders. Comparatively, 1.3% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate RXII or VTVT? vTv Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 133.96%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than RXi Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RXi Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer RXII or VTVT? vTv Therapeutics received 160 more outperform votes than RXi Pharmaceuticals when rated by MarketBeat users. However, 68.09% of users gave RXi Pharmaceuticals an outperform vote while only 57.80% of users gave vTv Therapeutics an outperform vote. CompanyUnderperformOutperformRXi PharmaceuticalsOutperform Votes19268.09% Underperform Votes9031.91% vTv TherapeuticsOutperform Votes35257.80% Underperform Votes25742.20% Which has preferable valuation and earnings, RXII or VTVT? RXi Pharmaceuticals has higher earnings, but lower revenue than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRXi Pharmaceuticals$10K770.88-$12.45M-$4.20-0.42vTv Therapeutics$1M47.72-$20.25M-$4.53-3.30 Is RXII or VTVT more profitable? vTv Therapeutics has a net margin of 0.00% compared to RXi Pharmaceuticals' net margin of -4,990.20%. vTv Therapeutics' return on equity of -184.64% beat RXi Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets RXi Pharmaceuticals-4,990.20% -412.15% -179.54% vTv Therapeutics N/A -184.64%-47.29% SummaryvTv Therapeutics beats RXi Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get RXi Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXII vs. The Competition Export to ExcelMetricRXi PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.71M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.4210.5990.0517.18Price / Sales770.88196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book2.295.094.784.78Net Income-$12.45M$151.83M$120.31M$225.60M RXi Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXIIRXi PharmaceuticalsN/A$1.76+1.1%N/A+128.8%$7.71M$10,000.00-0.42N/AGap DownVTVTvTv Therapeutics2.0082 of 5 stars$15.30+1.8%$35.00+128.8%+69.8%$48.81M$2.02M-3.329Gap UpCASICASI Pharmaceuticals3.083 of 5 stars$3.15+1.3%$6.00+90.5%-60.4%$48.70M$22.06M-1.39180XCURExicure0.88 of 5 stars$18.65+7.7%N/A+3,130.1%$48.68M$28.83M-9.2750News CoverageGap UpKZRKezar Life Sciences3.7131 of 5 stars$6.53-3.3%$40.50+520.2%-24.3%$47.64M$7M-0.5060Analyst ForecastNews CoverageALRNAileron Therapeutics3.0747 of 5 stars$2.16-4.4%$19.00+779.6%-41.9%$46.81MN/A-0.729Positive NewsRFLRafael0.7384 of 5 stars$1.90+0.8%N/A+7.1%$46.75M$640,000.00-1.1313Gap UpBIVIBioVie1.1579 of 5 stars$2.57-2.7%$3.00+16.7%+53.2%$45.66MN/A-0.2310NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M-0.0739Analyst ForecastVIRIVirios TherapeuticsN/A$2.36-2.1%$3.00+27.1%+300.7%$45.45MN/A-8.745GANXGain Therapeutics2.6702 of 5 stars$1.65+1.4%$7.25+338.6%-37.6%$43.85M$50,000.00-1.4820 Related Companies and Tools Related Companies VTVT Alternatives CASI Alternatives XCUR Alternatives KZR Alternatives ALRN Alternatives RFL Alternatives BIVI Alternatives NBRV Alternatives VIRI Alternatives GANX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RXII) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RXi Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share RXi Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RXII Stock Alerts